Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515778 | 0.92 | TGFBR1 (0.47) | BCHEHTR6TGFBR1USP7PIK3CD | |
| SCHEMBL515281 | 0.92 | TGFBR1 (0.47) | BCHEHTR6TGFBR1USP7PIK3CD | |
| SCHEMBL17394745 | 0.90 | GPR119 (0.46) | POLBTGFBR1USP7GPR119 | |
| SCHEMBL23897580 | 0.83 | PIK3CD (0.41) | BCHEHTR6TGFBR1USP7PIK3CD | |
| SCHEMBL29950127 | 0.83 | PIK3CD (0.41) | BCHEHTR6TGFBR1USP7PIK3CD | |
| SCHEMBL26811380 | 0.81 | GPR119 (0.46) | JAK3POLBJAK1PIK3CDGPR119 | |
| SCHEMBL23897651 | 0.81 | GPR119 (0.41) | PIK3CDGPR119 | |
| SCHEMBL31637367 | 0.79 | BRD4 (0.40) | JAK3NAMPTTGFBR1MEN1KMT2A | |
| SCHEMBL14806597 | 0.78 | FGFR1 (0.38) | MEN1KMT2AACACB | |
| SCHEMBL14806596 | 0.78 | FGFR1 (0.38) | MEN1KMT2AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410089-B2 | Fused heterocyclic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2399914-A1 | FUSED HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028962-A1 | FUSED HETEROCYCLIC RING COMPOUND | GPR119, GPR4, GPR84 | JAK3 2033/4885NAMPT 3717/4885BCHE 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.